Mar 14, 2023 / 06:00PM GMT
Matt Biegler - Oppenheimer & Co. Inc. - Analyst
Hey, everyone. Thanks for joining the OpCo Healthcare Conference. My name's Matt Biegler. If you don't know me, I'm a covering analyst.
Very pleased to introduce one of our next covered companies, which is Portage. They are working on a diverse set of immunomodulatory agents for cancer. Here to tell us more is CEO, Ian Walters. So Ian, if you want to run through the deck, it'd be great.
Ian Walters - Portage Biotech Inc. - Chairman & CEO
Thanks, Matt. Thanks very much for having us today. For those of you who are not familiar with Portage, we are an immuno-oncology company, and we have four clinical-stage assets that I'll be telling you about shortly.
With these assets, they're really designed to be in robust clinical trials that will show human proof of concept, and we have multiple different catalysts within the next two years. This is being led by a team from BMS that helped develop the leading drugs in that area.
And we also have what we refer to as a cost-effective business
Portage Biotech Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 14, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers